How persons with systemic mastocytosis describe the time between symptom onset and receiving diagnosis

Kerstin Hamberg Levedahl1, Annika Nilsson2, Birgitta Johansson3 and Mariann Hedström1

1Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden; 2Department of Caring Sciences, University of Gävle, Gävle, Sweden and 3Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

Abstract

Aim: The aim of the study was to explore how persons with systemic mastocytosis (SM) described the time between the onset of symptoms and signs and getting the diagnosis. Background: SM is a rare disease caused by the accumulation of clonal mast cells with abnormal function. The symptoms and signs of the disease are varied, often diffuse and affect individuals differently. Due to this complexity, a multi-disciplinary diagnostic approach is required, in which general practitioners play an important part in identifying and referring patients relevant for such investigations. Methods: Sixteen persons with SM were interviewed about their experiences of the time before the diagnosis was received. Systematic text condensation was used in the analysis process. Findings: The time between symptom and signs onset and diagnosis was perceived as difficult. SM often had a complex and unpredictable effect on a person’s daily life, long before diagnosis. In the analysis, three themes were found. Having symptoms and signs with an unknown cause included the participants’ descriptions of numerous symptoms and signs, often years before diagnosis. These could be severe and result in worries for both participants and their next-of-kin. Dealing with the symptoms and signs encompassed the different ways in which the participants coped with the symptoms and signs, and sought relief. Being a patient without a diagnosis underlined the lack of information and knowledge within healthcare, often resulting in a delayed or incorrect diagnosis. The study highlighted the importance of a person-centred approach and the need to increase knowledge of the disease within primary care, to shorten this stressful and vulnerable time.

Background

Systemic mastocytosis (SM) is a rare disease with an incidence just under one person in 100 000 (van Doormaal et al., 2013; Cohen et al., 2014). SM is caused by the accumulation of clonal mast cells with defective function (Valent et al., 2017). In many cases, SM is difficult to detect due to the range of symptoms and signs caused by the disease. Prolonged timespan between the first symptoms and diagnosis is common for these patients (Gülen et al., 2016; Valent et al., 2017). The diagnosis is determined by a pathological bone marrow sample, mutation D816V in the KIT gene and elevated serum total tryptase (Pardanani et al., 2021). In the diagnosis process, a multi-disciplinary investigation is often needed. General practitioners are important to identify and refer patients relevant for such investigations (Valent et al., 2019).

The debut of symptoms and signs often occur between the ages of 20 and 50 years, although the diagnosis is most commonly confirmed between the ages of 40 and 60 years (Gülen et al., 2016). The organs that are most commonly affected by SM are the skin, bones, bone marrow and the gastrointestinal tract. SM is divided into indolent SM (ISM) and advanced SM (AdvSM) (Pardanani et al., 2021). More females are affected by ISM (Cohen et al., 2014; Trizuljak et al., 2020; Fuchs et al., 2021) but slightly more men are affected by AdvSM (Kluin-Nelemans et al., 2021). Survival in ISM is in most cases equal to that in the normal population (Pardanani et al., 2019). The severity of ISM is not dependent on the duration of the disease, nor on the sex or age of the patient (Siebenhaar et al., 2018). AdvSM leads to infiltration of mast cells in organs and causes organ impairment with symptoms such as, e.g., transaminitis, malabsorption and severe osteoporosis (Scherber and Borate, 2018; Wagner and Staubach, 2018). AdvSM is uncommon and usually has a grave prognosis with significantly shortened life expectancy (Pardanani, 2021).

The symptoms and signs can include, e.g., skin and gastrointestinal (GI) problems, cognitive disabilities, depression and life-threatening anaphylactic reactions (Vermeiren et al., 2020; Pardanani et al., 2021). More than 4 of 10 patients have experienced anaphylactic reactions presenting as respiratory problems, low blood pressure, seizures, flush and skin reactions
Studies on the experiences of living with SM are still sparse and, to the best of our knowledge, no studies have focussed specifically on persons with ISM and AdvSM and their experiences before diagnosis. In a recent Danish study based on seven participants with ISM, some participants had experienced being seen as hypochondriacs by healthcare professionals before finally being diagnosed (Jensen et al., 2019). Increased knowledge about how the period from onset of symptoms to diagnosis is experienced may aid the diagnostics of the disease and provide a basis for the development of support interventions. The aim of this study was therefore to explore how persons with SM describe the time between onset of symptoms and signs and receiving the diagnosis.

Methods
This study had a qualitative explorative design.

Recruitment and participants
Persons with SM in Sweden can be treated either at a local hospital or be referred to one of two centres for mastocytosis, both located at university hospitals. Participants were recruited from one of these two centres. A purposive sample was used to obtain a variation in age, sex and the two different kinds of SM, ISM and AdvSM. To improve accessibility, only persons living in mid-Sweden were selected for participation in the study, but efforts were made to include persons from both small and large cities. Recruitment was conducted between November 2016 and April 2017. The inclusion criteria were the ability to speak and understand Swedish, being 18 years or older and having had the diagnosis SM confirmed through bone marrow biopsy. The exclusion criteria were severe comorbidity, cognitive impairment/disorder or alcohol/drug abuse. Seventeen eligible persons were approached by healthcare staff at the centre and all expressed interest to participate in the study. These were contacted by phone by the first author and given more information about the study. One participant was excluded due to cognitive impairment evident during the interview. Thus, the study group consisted of 16 participants (Table 1).

Interviews
Each participant chose the time and place for their interview. Before the interview started, the participant was asked to read the study information thoroughly and sign the informed consent if they chose to participate. Data were collected using semi-structured interviews. All interviews included questions regarding how it all began, symptoms, signs and triggers and how the various situations were handled. The emotions that these situations aroused in the participants and others around them were also addressed. Probing questions were asked when needed to get a more thorough description. Questions about how the participants described their experience of disease impact on daily life after being diagnosed were also included in the interviews. These results will be presented in a forthcoming publication. The interview guide was initially pilot-tested on one participant who was eligible for the study. No changes were considered necessary and this interview was included in the results. All interviews were performed by the first author and lasted 25–90 min (Md 60 min). Most of the interviews (13) took place at the participant’s home. The other three interviews took place at various locations, chosen by the participants.

Systematic text condensation analysis
Data were analysed with systematic text condensation, in accordance with Malterud’s description (Malterud, 2012). This is a step-by-step analysis that strengthens the empirical power of a study. The interviews were audio-recorded and thereafter transcribed verbatim. The analysis involved the following steps. The first author read the entire transcripts and four preliminary themes were identified; physical and psychosocial impact of the disease, management and treatment of symptoms, communication with healthcare professionals and deficiencies in care processes. The transcripts were thereafter systematically reviewed to find text connected to the aim of the study, so-called meaning units. Meaning units were marked with a code and sorted into code groups. As the analysis evolved, the names and scope of the code groups were adjusted. Meaning units in each code group of subsections were extracted into a condensate expressing their essence. As the analysis evolved, the names and scope of the code groups were adjusted. In this phase, the preliminary themes were reorganised into three final main themes and seven subsections. Thereafter, quotations that were representative for each subsection’s condensate were selected. The condensates from each subsection were thereafter reconceptualised into an analytic text reflecting the full context. The second and last author listened to random selections of recordings, read parts of the transcripts and participated in the analysis in an iterative process. The amount of empirical data needed to illuminate the aim of the study was considered reached (Malterud, 2012) and the final version of the analysis was approved by all authors. Description of the steps of the analysis process are presented in Table 2.
Results

The analysis resulted in three main themes: Having symptoms and signs with an unknown cause, Dealing with the symptoms and signs and Being a patient without a diagnosis. The themes with associated subsections are presented in Table 3. Quotes to define and enrich the descriptions are included in the results. The symbol / . . . / indicates an insignificant excluded statement.

Theme 1: having symptoms and signs with an unknown cause

Symptoms, signs and triggers

The participants described various symptoms and signs that had often appeared years before diagnosis. Many symptoms were related to skin problems, such as rashes, flushes and pruritus. It was common that the rashes grew in number and severity over time. For most participants with ISM, the skin symptoms were the main reason for seeking help from healthcare. Many mentioned that they had some kind of allergy before symptom onset. Some participants had been more tired than usual, and lack of concentration and mood changes were also described.

Most of the participants had experienced GI symptoms before diagnosis. These could consist of vomiting, diarrhoea and stomach pain. Frequent and severe diarrhoea that greatly disturbed everyday life was described as especially problematic by persons with AdvSM, but also by some of the participants with ISM. Almost all participants with AdvSM reported significant weight loss as an early sign of the disease.

I had a lot of diarrhoea before I got the diagnosis, I hardly dared go anywhere, it just ran out of me and I had to use diapers and lost 25 kilos in weight. It took eleven years before they figured out what was wrong (ID 13: ISM).

A serious symptom that was described by both participants with ISM and those with AdvSM was a kind of ‘attack’ that could appear very suddenly, with varying frequency. These attacks could consist of stomach pain, tachycardia and feeling drained of all power and not being able to communicate with the surroundings, and often resulted in fainting. The duration of the attacks could be hours.

I’d go out onto the pitch and do a 20-metre rush and suddenly I couldn’t breathe. It was like pushing a button and then like watching a cartoon. All my strength would just disappear, like when you empty a bottle. So I’d get up, I’d take a step but fall to my knees and try to crawl away, then everything turns black and I can’t remember anything more (ID 1: ISM).

The symptoms and signs could be triggered by various kinds of food, exercise, alcohol, sexual activity (including local reactions from semen) and exposure to changes in temperature, e.g., cold/warm weather or a hot shower. However, for many participants, the triggers were not always known. Most participants stated that the symptoms and signs greatly affected their life negatively prior to diagnosis, although some participants had not experienced any major impact on their daily life.

Worries: one’s own and others

The occurrence of attacks often resulted in vulnerable and exposed situations. This caused anxiety and fear, in part because the cause of the attacks was unknown. Many feared that they were going to die and struggled to find a reason for the attacks. When the attacks started, some feared that they were suffering from a heart attack or a stroke. The participants also described the worries among family, friends and colleagues, who could become very upset when a participant lost consciousness. Many participants had an ambulance called for them on multiple occasions.

Participants with AdvSM were afraid that their symptoms were caused by some sort of cancer, making the delay in diagnosis hard to bear. The diagnostic procedure could also be very worrying, exemplified in the quotation below.

When the doctor started talking about taking samples for some blood disease, I got really scared, just from hearing the words blood disease, that sounds horrifying, so I got a bit of a panic attack at first and could barely breathe, but then I understood that it wasn’t leukaemia (ID: 12, ISM).

Theme 2: dealing with the symptoms and signs

Self-care

The participants described trying various strategies to manage the symptoms and signs, e.g., dietary changes. Some excluded egg, gluten or milk and some tried something that they described as ‘anti-cancer food’. Some participants exposed their rashes to the sun to make them paler, although others found that sunlight made the rashes even worse. Non-prescription drugs like antihistamines and different kinds of ointments were also used to manage the symptoms. Thus, the diagnosis could sometimes be delayed by self-treatment.

I talked to a friend and she had stopped eating gluten, so I tried that too and I felt like it helped, that the diarrhoea got a bit better (ID: 7, ISM).

Seeking information

As it often took years to get the diagnosis, the participants and their next-of-kin performed searches in literature and on the internet, and asked around to try to find a relevant diagnosis themselves. However, the complex and diffuse symptoms and signs made that difficult. Some concluded that the rashes were due to normal ageing and were harmless. This meant that in several cases participants waited years, even decades, before seeking professional

Table 1. Characteristics for participants (n = 16)

| Background variables |   |
|----------------------|--|
| Sex                  |   |
| Female               | 12 |
| Male                 | 4  |
| Age (years)          |   |
| 31–40                | 1  |
| 41–50                | 1  |
| 51–60                | 1  |
| 61–70                | 8  |
| 71–80                | 3  |
| 81–90                | 2  |
| Time from first symptoms of disease to diagnosis |   |
| 0–33 years           |   |
| Time from diagnosis to interview |   |
| 0–16 years           |   |
| Type of systemic mastocytosis |   |
| Indolent             | 9  |
| Advanced             | 7  |
help. Some mentioned feeling embarrassed that they had kept the symptoms to themselves for so long.

My wife, who had been there, sat down and searched to see what it could be and got a hit for anaphylactic reaction. In the morning when I woke up, she said 'I think I know what you have.' /…/ and she pulled out a piece of paper and gave it to me. 'Look at that,' she said and I recognised all the criteria, I had every single one except that my throat hadn’t swelled up (ID: 18, ISM).

Theme 3: being a patient without a diagnosis
Lack of information and coordination
Almost all participants had sought healthcare for rashes, attacks with affected consciousness or severe diarrhoea and had experienced being told that the cause of the problems was unknown. It was frustrating and exhausting having to fight to get a diagnosis.

I went to the gastro unit and met a skilled physician, but he didn’t understand anything. I don’t know how many gastroscopies I had. I think I know what you have.’ /…/ and she pulled out a piece of paper and gave it to me. ‘Look at that,’ she said and I recognised all the criteria, I had every single one except that my throat hadn’t swelled up (ID: 13, ISM).

Being a patient without a diagnosis
Lack of information and coordination
Being met with belief
Being erroneously diagnosed

Table 3. Main themes and associated subsections

| Main themes | Subsections | Example of Meaning unit | Code | Condensate | Subsection | Analytic text | Final theme |
|-------------|-------------|-------------------------|------|------------|------------|--------------|-------------|
| Being a patient without a diagnosis | Being met with belief | Attacks of mastocytosis | I vomited, got severe diarrhoea, spots, palpitations and became red-skinned in the skin. I could also faint from vigorous exercise, when I ate, drank alcohol but sometimes I didn’t know why. | Symptoms, signs and triggers | A serious symptom that was described by both participants with ISM and those with AdvSM was a kind of “attack” that could appear very suddenly, with varying frequency. These attacks could consist of stomach pain, tachycardia, and feeling drained of all power and not being able to communicate with the surroundings, and often resulted in fainting. The duration of the attacks could be hours. | Having symptoms and signs with an unknown cause |

Table 2. The analyse process

| Preliminary theme | Example of Meaning unit | Code | Condensate | Subsection | Analytic text | Final theme |
|------------------|-------------------------|------|------------|------------|--------------|-------------|
| Physical and psychosocial impact of the disease | I took a glass of liqueur and felt very sick and woke up outside the toilet | Attacks of mastocytosis | I vomited, got severe diarrhoea, spots, palpitations and became red-skinned in the skin. I could also faint from vigorous exercise, when I ate, drank alcohol but sometimes I didn’t know why. | Symptoms, signs and triggers | A serious symptom that was described by both participants with ISM and those with AdvSM was a kind of “attack” that could appear very suddenly, with varying frequency. These attacks could consist of stomach pain, tachycardia, and feeling drained of all power and not being able to communicate with the surroundings, and often resulted in fainting. The duration of the attacks could be hours. | Having symptoms and signs with an unknown cause |
cancer. This caused them a lot of stress and afterwards led to anger and disbelief.

The doctor said ‘You are so sick, you don’t realise how sick you are.’ We didn’t understand at all, my husband and I. And then he said that we should start with me getting my breasts checked, because it’s in the breasts and I felt like no. And then I got some brochures about cancer and the end of life, and I was supposed to get a cancer nurse as well (ID: 6, AdvSM).

Discussion

To the best of our knowledge, this is the first qualitative study that focuses on how persons with indolent and advanced SM experience the time before diagnosis. The results provide an understanding of the participants’ life situations, how they managed these situations and their experiences of healthcare prior to getting an explanation for their altered health. Lack of knowledge, delays in getting a correct diagnosis and a mistrusting approach from healthcare were common.

Both ISM and AdvSM participants reported recurrent attacks years before their diagnosis. These attacks could be frightening for both the participants and their next-of-kin. Based on the descriptions, these attacks varied in severity, many resulting in emergency care. Anaphylactic reactions are common among patients diagnosed with SM (Gülen et al., 2014; Abid et al., 2016). However, based on the interview data, it is not possible to determine whether the described attacks met the criteria for anaphylaxis. Such attacks should lead to an investigation for a possible SM diagnosis (Gottlib et al., 2018). Some participants with AdvSM reported having severe symptoms and signs, e.g., severe diarrhoea and loss of weight, years before diagnosis. A delayed diagnosis is especially problematic under such circumstances and reflects that knowledge of the disease is limited in healthcare. Some participants diagnosed with AdvSM had first been given a cancer diagnosis, with a short life expectancy. Among these participants, AdvSM was seen as a non-malignant disease and the diagnosis came as a relief. This is surprising, as AdvSM is also a form of malign diagnosis with a dismal prognosis (Valent et al., 2014; Pardanani, 2021).

Most of the mentioned symptoms, signs and triggers have been reported before (Jennings et al., 2018; Valent et al., 2019; Pardanani, 2021), although contact with semen during sexual activity has not previously been described as a trigger, to our knowledge. Our results highlighted that the participants themselves managed symptoms and signs of the disease with a number of strategies, such as dietary changes or avoiding exposure to the sun. Participants and their relatives struggled to find answers online and by asking other people if they recognised the, often diffuse, symptoms and signs, which is similar to findings in an earlier study of persons with medically unexplained symptoms (Lidén et al., 2015). Persons with rare diseases often report the internet to be a source of easily accessible information in their search for a diagnosis but also point to the fact that the information found there may not always be reliable (von der Lippe et al., 2017; Littzkendolf, et al. 2020).

After repeatedly seeking care without there being an explanation to the problems, sometimes resulting in feelings of not being believed and of embarrassment, the participants did not see any point in contacting healthcare, instead, they relied on self-care or ignored the symptoms. Several studies report on the importance of getting a diagnosis and an explanation for medically unexplained symptoms (Jennings et al., 2014; Garrino et al., 2015; Walklet et al., 2018; Jensen et al., 2019). Meeting the ‘right’ physician, a physician who was interested in finding a cause for the symptoms the patient presented and who did not stop searching for an explanation, appeared crucial for receiving the correct diagnosis. An interview study of 20 physicians who cared for patients presenting with medically unexplained symptoms revealed a need for education and structure in the care of such patients (Warner et al., 2017). Delay in diagnosis due to lack of knowledge among healthcare professionals is common for many rare diseases (von der Lippe et al., 2017; Llubes-Arría et al., 2021). For general practitioners, it is a major challenge to have knowledge of rare diseases since, in the Orphanet database, there are 6172 different rare diseases registered (Ngueang Wakapet al., 2020). A recent meta-synthesis (Johansen and Risor, 2017) called for integration of the doctor and patient perspectives and stressed the importance of striving for person-centeredness in physicians’ management strategies.

Methodological considerations

The first author is a registered nurse with extensive experience working with this patient group and thus has a preunderstanding of SM, but she had not previously met any of the participants. According to Malterud (2001), preconceptions may affect a study in both positive and negative ways. During all steps of the study, the first author made an effort to identify her preconceptions and reflect on these with the other authors. None of the co-authors had any experience of working with this patient group and could, with this naivety, strengthen the reflective process (Malterud, 2001). The study’s trustworthiness (Guba and Lincon, 1991) was strengthened as the transcribed interviews were continuously reviewed, the analysis method was well-established (Malterud, 2012) and the co-authors were all experienced in qualitative analysis.

The participants in this study were positive about sharing their experiences and none declined participation. The notion that the experiences shared were related to SM is supported, as all had their diagnosis confirmed through bone marrow biopsy and none had any severe co-morbidity. The participants included both women and men, representing various ages and places of residence and both ISM and AdvSM. Most of the symptoms and triggers that the participants mentioned have been reported previously. Even though the period during which the participants were diagnosed exceed 15 years, this was a time when the diagnostic and medical procedures for SM were basically unchanged (Arock et al., 2020) and the extended diagnostic period has therefore probably not affected the results markedly. The median length of the interviews was 60 min, which was ample for getting extensive and varied data with high information power. However, some limitations must be addressed. User involvement is important to ensure that patients get the opportunity to influence their care and create confidence in the healthcare. Further user involvement can improve research. In the study planning process, we could have asked persons living with SM to share their perspectives on relevant aspects of the study design, e.g., the interview guide. User reflections and lived experience can also add a valuable layer to the analytic phase (Locock et al., 2019). Involving users in reading and discussing a version of the results before finalisation would probably have strengthened our study’s credibility and transferability.

There was an overrepresentation of female participants. Thus, male perspectives may not be sufficiently covered, thereby possibly lowering both the internal validity and the transferability of the results. It is known that sex inequalities exist in primary care, as
women receive fewer examinations and specialist referrals than men (Ballering et al., 2021). Similarly, although the intention was that the sample would consist of variation in the age distribution that reflects the variety in the patient group, there was a greater representation of slightly older persons. Thus, experiences from younger individuals may be underrepresented in the results. However, there is a variety of experiences described and these are valuable regardless of how many participants in different ages that have described them. Those who did not speak Swedish were excluded, which also limited the variation in the sample. Furthermore, the sample consisted mainly of patients with more severe diseases, since all patients had at some point been referred to a university hospital. However, the study’s explorative design means that a description of all possible patient experiences of the subject is not required (Malterud, 2012). The time from symptom onset until diagnosis and the time that the participants had lived with the diagnosis prior to their interview varied. There is a risk that memories of the time between symptom onset and diagnosis in some cases might have changed over time, so-called recall bias (Raphael, 1987). However, it is argued that emotionally significant experiences are remembered more clearly (Roozendaal and McGaugh, 2011). The fact that the participants’ descriptions of the period before diagnosis were detailed and vividly narrated supports the notion that it was well-remembered.

Clinical implications

General practitioners are often the first to meet patients who present symptoms and signs that are consistent with SM. These symptoms and signs can be diffuse and the patients are at risk for a delayed or missed diagnosis. If not taken seriously, patients might stop seeking medical care. The current study underlines the importance of listening carefully to the patients’ descriptions. When patients describe symptom clusters including some or all of the following: mild to severe gastrointestinal symptoms, pruritus, flushing and skin rashes, allergy with various triggers, recurrent syncope or anaphylaxis, declined cognitive ability or mood swings, general practitioners should consider referring these persons to specialist care for further investigation.

Conclusion

The time between symptom onset and diagnosis was perceived as difficult, with severe, complex and often unpredictable symptoms that the participants had to deal with on their own, often for many years. The healthcare deficiency in diagnosing and supporting these persons highlights the importance of a person-centred approach and the need to increase knowledge of SM within healthcare, in order to shorten this stressful and vulnerable time.

Acknowledgments. We wish to thank all the participants for sharing their experiences with us.

Ethical Standards. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional guidelines on human experimentation (The Swedish Code of Statutes, 2003:460) and with the Helsinki Declaration of 1975, as revised in 2008. This study was approved by Swedish Ethical Review Authority (Dnr 2016/182). Written informed consent was obtained from all participants.

Financial support. This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Conflict of interest. None.

References

Abid A, Malone MA and Curci K (2016) Mastocytosis. Primary Care 43, 505–518.
Arock M, Sotlar K, Gotlib J, Sperr WR, Hartmann K, Schwartz LB, Akin C, Horny HP and Valant P (2020) New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. Leukemia & Lymphoma 61, 1075–1108.
Ballering AV, Muijres D, Uijen AA, Rosmalen JGM and Olde Hartman TC (2021) Sex differences in the trajectories to diagnosis of patients presenting with common somatic symptoms in primary care: an observational cohort study. Journal of Psychosomatic Research 149, 110589.
Cohen SS, Skovbo S, Vestergaard H, Kristensen T, Møller M, Bindslev-Jensen C, Fryzek JP and Broesby-Olsen S (2014) Epidemiology of systemic mastocytosis in Denmark. British Journal of Haematology 166, 521–528.
P. Fuchs D, Kilbertus A, Kofler K, Von Bubnoff N, Shoumariyeh K, Zanotti R, Bonadonna P, Scaffidi L, Doubek M, Elberink HO, Span LFR, Hermine O, Elena C, Benvenuti P, Yavuz AS, Brockow K, Zink A, Aberer E, Gorska A, Romantowski J, Hadzijusufovic E, Fortina A, Caroppo F, Perkins C, Illerhaus A, Panse J., Vucinic V, Jawhar M, Sabato V, Triggiani M, Parente R, Bergström A, Breynaert C, Gotlib J, Reiter A, Hartmann K, Niedoszytko M, Arock M, Kluin-Nelemans HC, Sperr WR, Greul R and Valant P (2012) Scoring the risk of having systemic mastocytosis in adult patients with Mastocytosis in the skin. The Journal of Allergy and Clinical Immunology: In Practice 9, 1705–1712.e4.
Garrino L, Picco E, Finiguerra I, Rossi D, Simone P and Roccatello D (2015) Living with and treating rare diseases: experiences of patients and professional health care providers. Qualitative Health Research 25, 636–651.
Gotlib J, Gerds AT, Bøse P, Castells MC, Deininger MW, Gojo I, Gundakolu K, Hobbs G, Jamesion C, McMahan B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podolsney R, Rampal R, Ramhein E, Rein I, Snyder DS, Stein BL, Talpaz M, Thota S, Wadhile M, Walsh K, Bergman MA and Sundar H (2018) Systemic mastocytosis, version 2.2019, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network: JNCCN 16, 1500–1537.
Guba EG and Lincon YS (1991) Naturalistic inquiry. Thouand Oaks, CA: SAGE Publications.
Gülen T, Hägglund H, Dahlén B and Nilsson G (2014) High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 44, 121–129.
Gülen T, Hägglund H, Dahlén B and Nilsson G (2016) Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease. Journal of Internal Medicine 279, 211–228.
Gülen T, Hägglund H, Dahlén S-E, Sander B, Dahlén B and Nilsson G (2014) Flushing, fatigue, and recurrent anaphylaxis: a delayed diagnosis of mastocytosis. The Lancet 383, 1608.
Henningsen P, Zipfel S and Herzog Z (2007) Management of functional somatic syndromes. Lancet (London, England) 369, 946–955.
Huyard C (2009) What, if anything, is specific about having a rare disorder? Patients’ judgements on being ill and being rare. Health Expectations: An International Journal of Public Participation in Health Care and Health Policy 12, 361–370.
Jennings S, Russell N, Jennings B, Slee V, Sterling L, Castells M, Valant P and Akin C (2014) The Mastocytosis society survey on mast cell disorders: patient experiences and perceptions. The Journal of Allergy and Clinical Immunology: In practice 2, 70–76.
Jennings SV, Slee VM, Zack RM, Verstovsek S, George TI, Shi H, Lee P and Castells MC (2018) Patient perceptions in mast cell disorders. Immunology and Allergy Clinics of North America 38, 505–525.
Jensen B, Broesby-Olsen S, Bindslev-Jensen C and Nielsen DS (2019) Everyday life and mastocytosis from a patient perspective- a qualitative study. Journal of Clinical Nursing 28: 1114–1124.
Johansen ML and Risor MB (2017) What is the problem with medically unexplained symptoms for GPs? A meta-synthesis of qualitative studies. Patient Education and Counseling 100, 647–654.
Cluin-Nelemans HC, Jawhar M, Reiter A, van Anrooij B, Gotlib J, Hartmann K, Illerhaus A, Oude Elberink HNG, Gorska A, Niedoszytko M, Lange M, Scaffidi I, Zanotti R, Bonadonna P, Perkins C, Elena C, Malcovati I, Shoumaryieh K, von Bubnoff N, Müller S, Triggiani M, Parente R, Schwab J, Kundi M, Fortina AB, Caroppo F, Brockow K, Zink A, Fuchs D, Angelova-Fischer I, Yavuz, AS, Douchek M, Mattson M, Haggglund H, Panse J, Simonowski A, Sabato V, Schug T, Jentzsch M, Breynaert C, Várkonyi J, Kennedy V, Hermine O, Rossignol J, Arock M, Valentin P and Sperr WR (2021) Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. Theranostics 11, 292–303.

Liden E, Björk-Brämbärg E and Svensson S (2015) The meaning of learning to live with medically unexplained symptoms as narrated by patients in primary care: a phenomenological-hermeneutic study. International Journal of Qualitative studies on Health and Well-being 10, 27191.

Litzkendorf S, Frank M, Babac A, Rosenfeldt D, Schauer F, Hartz T and Graf von der Schulenburg JM (2020) Use and importance of different information sources among patients with rare diseases and their relatives over time: a qualitative study. BMC Public Health 20, 860.

Llubes-Arríá L, Sanromà-Ortiz M, Torné-Ruiz A, Carillo-Álvez E, García-Exposito J and Roca J (2022) Emotional experience of the diagnostic process of a rare disease and the perception of support systems: a scoping review. Journal of Clinical Nursing 31, 20–31.

Locock L, Kirkpatrick S, Brading L, Sturmey G, Cornwell J, Churchill N and Litzkendorf S, Frank M, Babac A, Rosenfeldt D, Schauer F, Hartz T and Graf von der Schulenburg JM (2020) Use and importance of different information sources among patients with rare diseases and their relatives over time: a qualitative study. BMC Public Health 20, 860.

Malterud K (2001) Qualitative research: standards, challenges, and guidelines. Lancet (London, England) 358, 483–488.

Malterud K (2012) Systematic text condensation: a strategy for qualitative analysis. Scandinavian Journal of Public Health 40, 795–805.

Nettleton S (2006) ‘I just want permission to be ill’: towards a sociology of medically unexplained symptoms. Social Science & Medicine 62, 1167–1178.

Nguegeng Wakap S, Lambert DM, Olyr A, Rodwell C, Gueydan C, Lanneau V, Murphy D, Le Cam Y and Rath A (2020) Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. European Journal of Human Genetics 28, 165–173.

Pardanani A (2021) Systemic mastocytosis in adults. 2021 Update on diagnosis, risk stratification and management. American Journal of Hematology 102, 508–525.

Pardanani A, Lasho TL, Reichard KK, Hanson CA and Tefferi A (2019) World health organization class-independent risk categorization of mastocytosis. Blood Cancer Journal 9, 29.

Raphael K (1987) Recall bias: a proposal for assessment and control. International Journal of Epidemiology 16, 167–170.

Rasmussen EB (2020) Making and managing medical anomalies: exploring the classification of ‘medically unexplained symptoms’. Social Studies of Science 50, 901–931.

Roozenendaal B and McGaugh JL (2011) Memory modulation. Behavioral Neuroscience 125, 797–824.

Scherber RM and Borate U (2018) How we diagnose and treat systemic mastocytosis in adults. British Journal of Haematology 180, 11–23.

The Swedish Code of Statutes 2003:460 (2003). Act on Ethical Review of Research Involving Humans). Stockholm: Utbildningsdepartementet. (Ministry of Education and Research). https://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/lag-2003460-om-etikprovning-av-forskning-som-sfx-2003-460 (accessed 15 June 2022).

Siebenhaar F, Sander B, Ho LHT, Elrich A, Maurer M and Weller K (2018) Development and validation of the mastocytosis activity score. Allergy 73, 1489–1496.

Trizuljak J, Sperr WR, Nekvindova I, Elberink HO, Gleixner KV, Gorska A, Lange M, Hartmann K, Illerhaus A, Bonifacio M, Perkins C, Elena C, Malcovati I, Fortina AB, Shoumaryieh K, Jawhar M, Zanotti R, Bonadonna P, Caroppo F, Zink A, Triggiani M, Parente R, Von Bubnoff N, Yavuz AS, Hägglund H, Mattsson M, Panse J, Jäkel N, Kilbertus A, Hermine O, Arock M, Fuchs D, Sabato V, Brockow K, Bretterkleiber A, Niedoszytko M, Van Anrooij B, Reiter A, Gotlib J, Cluin-Nelemans HC, Mayer J, Douchek M and Valentin P (2020) Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. Allergy 75, 1927–1938.

Valentin P, Akin C, Gleixner KV, Sperr WR, Reiter A, Arock M and Triggiani M (2019) Multidisciplinary challenges in mastocytosis and how to address with personalizedmedicine approaches. International Journal of Molecular Sciences 20, 2976.

Valentin P, Akin C and Metcalfe DD (2017) Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 129, 1420–1427.

Valentin P, Oude Elberink JNG, Gorska A, Lange M, Zanotti R, van Anrooij B, Bonifacio M, Bonadonna P, Gleixner KV, Hadzijušuvicovific E, Perkins C, Hartmann K, Illerhaus A, Merante S, Elena C, Shoumaryieh K, von Bubnoff N, Parente R, Triggiani M, Schwaab J, Jawhar M, Caroppo F, Fortina AB, Brockow K, David F, Greul R, Yavuz AS, Douchek M, Mattsson M, Hägglund H, Panse J, Sabato V, Aberer E, Al-Ali HK, Morren MA, Varkonyi J, Zink A, Niedoszytko M, Niederwieser D, Malcovati I, Reiter A, Kennedy V, Gotlib J, Lortholary O, Hermine O, Arock M, Cluin-Nelemans H and Sperr WR (2019) The data registry of the European competence network on Mastocytosis (ECNM): Set up, projects, and perspectives. The Journal of Allergy and Clinical Immunology: In Practice 7, 81–87.

van Doormaal JJ, Arends S, Brunekreef KL, van der Wal VB, Sietsma J, van Voorst Vader PC, Oude Elberink JN, Cluin-Nelemans JC, van der Veer E and de Monchy JG (2013) Prevalence of indolent systemic mastocytosis in a Dutch region. The Journal of Allergy and Clinical Immunology 131, 1429–31.e1421.

Vermeiren MR, Kraanenburg LW, van Dalec PLA, Gerth van Wijk R and Hermans MAW (2020) Psychological functioning and quality of life in patients with mastocytosis: a cross-sectional study. Annals of Allergy, Asthma & Immunology 124, 373–378 e372.

Von Der Lippe C, Diesen PS and Feragen KB (2017) Living with a rare disorder: a systematic review of the qualitative literature. Molecular Genetics & Genomic Medicine 5, 758–773.

Wagner N and Staubach P (2018) Mastocytosis – pathogenesis, clinical manifestation and treatment. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology: JDDG 16, 42–57.

Walket E, Taylor C, Bradley E, Mahoney B, Scurlock-Evans L and O’Hickey S (2018) ‘Because it kind of falls in between, doesn’t it? Like an acute thing and a chronic it?’ The psychological experience of anaphylaxis in adulthood. Journal of Health Psychology 23, 1579–1589.

Warner A, Walters K, Lamahewa K and Buzszeicz M (2017) How do hospital doctors manage patients with medically unexplained symptoms: a qualitative study of physicians. Journal of the Royal Society of Medicine 110, 65–72.